2020/11/02

UKセッション/UK Session

英国におけるヘルスケアベンチャー創出の取り組み
/The Initiatives to create healthcare ventures in the UK


Innovate UK, Innovation lead (精密医療),Karen Spink⽒/Karen Spink, PhD,
Innovation lead‐Precision medicine, Innovate UK
WEB写真(Dr. Spink).jpg

[Summary]
This presentation described the importance of innovation to the future growth and prosperity of the UK. The UK has a vibrant innovation ecosystem, attracting approximately 38% of the total European venture capital investment in 2019 and considered within the top 10 best countries worldwide to start, locate and scale businesses. Evidence was presented during this talk of a rich history of high-quality research collaboration between UK and Japan as well as shared priorities across the innovation landscape.

The COVID-19 pandemic has highlighted the importance of science and innovation in responding to societal challenges, particularly in the health and life sciences. We are entering a new era in healthcare, driven by innovation in genomics, data, AI, and advanced therapies. These advances are enabling earlier and more personalized detection and diagnosis of disease biomarkers as well as the opportunity to improve the monitoring and treatment of patients outside of the hospital in community settings. Within an ageing population, earlier detection and better management of health conditions will support improvements to average healthy life years.

Innovate UK is the UK's innovation agency with a key role in driving productivity and economic growth by supporting businesses to develop their ideas and to grow and scale. Innovate UK has invested around £1.2Bn since 2007 in healthcare innovation across the UK. Funding delivered by Innovate UK has supported diverse business-led collaborative R&D projects to de-risk innovative ideas, attract venture capital, and support the route to market. Innovate UK is also at the heart of delivering the UK Government's Industrial Strategy Challenge Fund that has supported key innovation infrastructure such as digital pathology and AI-augmented radiology as well as advanced therapy manufacturing and treatment centres.

[Profile]
Karen is Innovation Lead for Precision Medicine at Innovate UK, responsible for investing on behalf of the UK government to support commercial development of technologies for early detection, diagnosis and precise treatment of disease. Major programmes currently being delivered include the whole genome sequencing of 500K UK Biobank participants as well as AI-enabled digital pathology & medical imaging. Innovate UK also continues to play a critical role in supporting UK businesses to re-purpose their technologies in response to the COVID-19 pandemic and to promote a sustainable economic recovery.
Karen has over 20 years of experience in leading collaborative R&D and the commercial translation of innovation. This includes nearly a decade at Pfizer leading emerging therapeutic programmes such as RNAi as well as being a founding member of a virtual drug discovery company. Karen has also led consortia involving Biotech, NHS, and academic stakeholders to develop robust clinical diagnostics for non-invasive whole-genome profiling of cancerous tumours.
Karen holds a PhD and BSc in Biochemistry & Genetics from The University of Nottingham.

CGTカタパルトの紹介
/The Introdaction of Cell Gene Therapy Catapult


CGTカタパルト Partnership Mgr-Asia,Shirley Lam⽒
Shirley Lam, PhD, Business Development Mgr.‐Asia, CGTCATAPULT
WEB写真(Dr. Lam).jpg

[Summary]
The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 230 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

[Profile]
Ms. Shirley Lam is the Business Development Manager for Asia at the Cell and Gene Therapy Catapult in the UK. She is responsible for developing business and partnerships with advanced therapy companies and research institutes in Asia Pacific, as well as building the business strategy for this territory. Prior to joining the Catapult, Shirley spent five years developing innovation partnerships between the UK and Asia to facilitate joint R&D, knowledge transfer and trade in the health and technology sectors. She also worked on research projects in various labs in the UK and Hong Kong. Her expertise spans across research, business/partnership development, project management, technology transfer and marketing.
Shirley obtained her MSc in Infection and Immunity from University College London and BSc in Medical Biochemistry from King's College London in the UK.

質疑+QA

モデレーター:ケンブリッジコンサルタンツ(株) 代表取締役社⻑佐相宏尚⽒/Moderator: Hirotaka Saso, Country Mgr., JAPAN, Cambridge Consultants

Saso_talk2.jpg